Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of Small Cell Lung Cancer
With the in-depth study of tumor immunity, immunotherapy represented by immune checkpoint inhibitors has made a great breakthrough in solid tumors. Small cell lung cancer (SCLC) accounts for about 15%-20% of all lung cancers, with high malignancy, early metastasis and lack of effective treatment str...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2019-04-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.07 |
| _version_ | 1818277922495004672 |
|---|---|
| author | Benlin HUANG Yong DUAN |
| author_facet | Benlin HUANG Yong DUAN |
| author_sort | Benlin HUANG |
| collection | DOAJ |
| description | With the in-depth study of tumor immunity, immunotherapy represented by immune checkpoint inhibitors has made a great breakthrough in solid tumors. Small cell lung cancer (SCLC) accounts for about 15%-20% of all lung cancers, with high malignancy, early metastasis and lack of effective treatment strategy. The appearance of immune checkpoint inhibitors brings new hope for SCLC. Several clinical trials have demonstrated the persistent efficacy and clinical activity of the programmed death receptor/ligand 1 (PD-1/L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) in the treatment of SCLC. However, its efficacy and safety are not very accurate, and the markers that can effectively predict the efficacy of immunotherapy have not been concluded. In this paper, for further changing the treatment strategy of SCLC clinical practice and providing theoretical basis of research, we reviewed the progress of immune checkpoint inhibitors, related markers in the treatment of SCLC by exploring the value, problems and challenges of immunotherapy in SCLC. |
| first_indexed | 2024-12-12T23:09:14Z |
| format | Article |
| id | doaj.art-bbf9c0cb8cd84758b08512232a848c9c |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-12T23:09:14Z |
| publishDate | 2019-04-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-bbf9c0cb8cd84758b08512232a848c9c2022-12-22T00:08:38ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872019-04-0122423924410.3779/j.issn.1009-3419.2019.04.07Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of
Small Cell Lung CancerBenlin HUANG0Yong DUAN1Department of Clinical Laboratory, the First Affiliated Hospital of Kunming Medical University; Yunnan Institute of Experimental Diagnosis; Yunnan Key Laboratory of Laboratory Medicine, Kunming 650032, ChinaDepartment of Clinical Laboratory, the First Affiliated Hospital of Kunming Medical University; Yunnan Institute of Experimental Diagnosis; Yunnan Key Laboratory of Laboratory Medicine, Kunming 650032, ChinaWith the in-depth study of tumor immunity, immunotherapy represented by immune checkpoint inhibitors has made a great breakthrough in solid tumors. Small cell lung cancer (SCLC) accounts for about 15%-20% of all lung cancers, with high malignancy, early metastasis and lack of effective treatment strategy. The appearance of immune checkpoint inhibitors brings new hope for SCLC. Several clinical trials have demonstrated the persistent efficacy and clinical activity of the programmed death receptor/ligand 1 (PD-1/L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) in the treatment of SCLC. However, its efficacy and safety are not very accurate, and the markers that can effectively predict the efficacy of immunotherapy have not been concluded. In this paper, for further changing the treatment strategy of SCLC clinical practice and providing theoretical basis of research, we reviewed the progress of immune checkpoint inhibitors, related markers in the treatment of SCLC by exploring the value, problems and challenges of immunotherapy in SCLC.http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.07Immune checkpoint inhibitorsSmall cell lung cancerPD-1PD-L1CTLA-4 |
| spellingShingle | Benlin HUANG Yong DUAN Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of Small Cell Lung Cancer Chinese Journal of Lung Cancer Immune checkpoint inhibitors Small cell lung cancer PD-1 PD-L1 CTLA-4 |
| title | Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of
Small Cell Lung Cancer |
| title_full | Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of
Small Cell Lung Cancer |
| title_fullStr | Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of
Small Cell Lung Cancer |
| title_full_unstemmed | Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of
Small Cell Lung Cancer |
| title_short | Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of
Small Cell Lung Cancer |
| title_sort | clinical research progress of immune checkpoint inhibitors in the treatment of
small cell lung cancer |
| topic | Immune checkpoint inhibitors Small cell lung cancer PD-1 PD-L1 CTLA-4 |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.07 |
| work_keys_str_mv | AT benlinhuang clinicalresearchprogressofimmunecheckpointinhibitorsinthetreatmentofsmallcelllungcancer AT yongduan clinicalresearchprogressofimmunecheckpointinhibitorsinthetreatmentofsmallcelllungcancer |